Acute pancreatitis and euglycemic non-diabetic ketoacidosis caused by an intentional semaglutide overdose
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have been approved for weight loss and have gained popularity for its efficacy and a once-weekly administration. The FDA approved max dose of 2.4 mg per week resulted in a 10 % reduction in weight over a 6-month peri...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | JEM Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2773232025000033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|